Is There a Border Between the Public and Private Sectors in Health Care?

• Authors: Nojszewska Ewelina
• Languages of publication: PL EN

Abstracts

EN

Diseases and their treatment affect the economy and the society by means of complicated transmission mechanisms. They include costs of treatment, i.e. direct costs, and indirect costs, i.e. lost GDP. Their impact on public finance revenues and expenditures should also be taken into account. Due to the importance of the problem of health as well as the quality and efficiency of the operation of the health care system, additional measures like a deadweight loss and a loss of wellbeing are considered. The effects of the mutual interaction of health and economic growth cannot be overlooked. The complexity of the on-going processes is further exacerbated as a result of the influence of the public and private sectors, which cannot be clearly demarcated in health care.

Keywords

EN

health care; indirect costs; deadweight loss; loss of well-being; economic growth

• Publisher: Uniwersytet Warszawski. Wydział Nauk Ekonomicznych
• Journal: Problemy Zarządzania
• Year: 2018
• Issue: 5/2018 (78)
• Pages: 11-21

Dates

online

2019-01-28

Contributors

author

Nojszewska Ewelina

• Collegium of Management and Finance, Warsaw School of Economics

References

• 1. Access Economics. (2008). The health of nations: The value of a statistical life. Report for the Office of the Australian Safety and Compensation Council (OASCC), January, Canberra.
• 2. Bates, W. (2001). How much government? The effects of high government spending on economic performance. New Zealand Roundtable. Retrieved from: https://nzinitiative.org.nz/reports-and-media/reports/how-much-government/.
• 3. Becker, G.S. (1962). Investment in human capital: A theoretical analysis. The Journal of Political Economy, 70(5), 9–49.
• 4. Bloom, D.E., Canning D., & Sevilla, J. (2004). The effect of health on economic growth: Theory and evidence. World Development, 32(1). https://doi.org/10.3386/w8587. Retrieved from: http://www.nber.org/papers/w8587.
• 5. Campbell, H. (1997). Deadweight loss and the cost of public funds in Australia. Agenda: A Journal of Policy Analysis and Reform, 4(2), 231–36.
• 6. Deloitte. (2015). The economic impact of diabetic macular oedema in Australia. Bayer Australia Ltd. Sydney: Deloitte Access Economics Pty Ltd.
• 7. Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes (4th ed.). Oxford: Oxford University Press.
• 8. EY. (2013). Metodyka pomiaru kosztów pośrednich w polskim systemie ochrony zdrowia, Warszawa: Ernst & Young.
• 9. EY. (2015). Innowacyjne terapie onkologiczne, propozycja poprawy polskiego systemu opieki onkologicznej. Warszawa: Ernst & Young/Pracodawcy Rzeczypospolitej Polskiej.
• 10. Feldstein, M. (1999). Tax avoidance and the deadweight loss of the income tax. Review of Economics and Statistics, 81(4), 676–677.
• 11. Fiscella, K., & Franks, P. (1997). Poverty or income inequality as predictor of mortality: Longitudinal cohort study. BMJ Clinical Research, 314, 1724–1727.
• 12. Fogel, R. W. (1994). Economic growth, population theory, and physiology: The bearing of long-term process on the making of economic policy. The American Economic Review, 84(3), 369–395.
• 13. Hermanowski, T. (Ed.). (2013). Szacowanie kosztów społecznych choroby i wpływu stanu zdrowia na aktywność zawodową i wydajność pracy. Warszawa: Wolters Kluwer Business.
• 14. Jo, C. (2014). Cost-of-illness studies: Concepts, scopes, and methods. Review Clinical and Molecular Hepatology, 20(4), 327–337. http://dx.doi.org/10.3350/cmh.2014.20.4.327.
• 15. Leppo, K., Ollila, E., Pena, S., Wismar, M., & Cook, S. (Eds.). (2013). Health in all policies. Seizing opportunities, implementing policies. Finland: Ministry of Social Affairs and Health. Retrieved from http://www.euro.who.int/__data/assets/pdf_file/0007/188809/Health-in-All-Policies-final.pdf.
• 16. INFARMA. (2014). Koszty pośrednie w ocenie technologii medycznych w Polsce. Raport Związku Innowacyjnych Firm Farmaceutycznych INFARMA. Retrieved from https://www.infarma.pl/assets/files/raporty/Raport_Koszty_posrednie_w_ocenie_technologii_medycznych_01.pdf.
• 17. Murray, C., & Lopez, A. (1996). The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Volume 1: Global Burden of Disease and Injury Series. Harvard: Harvard School of Public Health.
• 18. New Zealand Treasury. (2005). Cost benefit analysis primer. Wellington: The Treasury. Retrieved from https://treasury.govt.nz/sites/default/files/2015-07/cba-guide-jul15.pdf.
• 19. Nojszewska, E. (2016a). Społecznoekonomiczne czynniki determinujące status zdrowotny społeczeństwa na przykładzie Polski. Ekonomia i Prawo w Ochronie Zdrowia, 1, 59–74.
• 20. Nojszewska, E. (Ed.). (2016). Ocena strat ekonomicznych i kosztów leczenia nowotworów piersi, szyjki macicy i jajnika w Polsce. Warszawa: Instytut Innowacyjna Gospodarka.
• 21. O’Mahony, M., & Van Ark, B. (2003). EU productivity and competitiveness: An industry perspective. Can Europe resume the catching-up process? Luxembourg: European Commission.
• 22. Park, M., Braun, Th., Carrin, G., & Evans, D.B. (2007). Provider payments and cost-containment. Lessons from OECD countries. Technical Brief for Policymakers, 2. Geneva: World Health Organization. Retrieved from http://www.who.int/health_financing/documents/pb_e_07_2-providerpay_oecd.pdf.
• 23. Rice, D. P. (1967). Estimating the cost of illness. American Journal of Public Health and the Nation’s Health, 57(3), 424–440.
• 24. Robertson, A. (2007). No free lunch: The costs of taxation. New Zealand Business Roundtable.
• 25. Saha, S., & Gerdtham, U.G. (2013). Cost of illness studies on reproductive, maternal, newborn, and child health: A systematic literature review. Health Economics Review, 3(24). https://doi.org/10.1186/2191-1991-3-24.
• 26. Smaga, A., Mikułowska, M., Komorowska, A., Falkiewicz, B., & Gryglewicz, J. (2014). Rak piersi w Polsce – leczenie to inwestycja. Warszawa: Sequence HC Partners Sp. z o.o.
• 27. Stiglitz, J. E. (2004). Ekonomia sektora publicznego. Warszawa: PWN.
• 28. Suhrcke M., McKee, M., Sauto Arce, R., Tsolova, S., & Mortensen, J. (2005). The contribution of health to the economy in the European Union. Belgium: European Commission. Retrieved from http://ec.europa.eu/health/ph_overview/Documents/health_economy_en.pdf.
• 29. Viscusi, W.K., & Aldy, J.E. (2003). The value of a statistical life: a critical review of market estimates throughout the world. Journal of Risk and Uncertainty, Springer, 27(1), 5–76.
• 30. World Health Organization. (1999). Health21. The health for all policy framework for the WHO European Region. European Health for All Series No. 6. Copenhagen: World Health Organization. Retrieved from http://www.euro.who.int/__data/assets/pdf_file/0010/98398/wa540ga199heeng.pdf.
• 31. World Health Organization. (2008). The global burden of disease: 2004 update. Geneva: World Health Organization. Retrieved from http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/.
• 32. World Health Organization. (2009). WHO guide to identifying the economic consequences of disease and injury. Geneva: World Health Organization. Department of Health Systems Financing. Health Systems and Services.
• 33. Władysiuk, M., Hałdaś, M., Bebrysz, M., Fedyna, M., & Rutkowski, J. (2015). Przewlekłe choroby zapalne uwarunkowane immunologicznie – ocena kosztów pośrednich w Polsce. In B. Samoliński, F. Raciborski, J. Gołąb (Eds.), Konstruktywni – zdrowie, aktywność i zdolność do pracy (pp. 145–206). Warszawa: Wydawnictwo Naukowe Scholar.
• 34. World Bank. (1980). World development report. Washington: World Bank.
• 35. World Bank. (1993). Investing in health. World Development Report No 1993. New York: Oxford University Press.
• 36. Zamora, J. (2000). Investment in health and economic growth: a perspective from Latin America and the Caribbean. 35th meeting of the Advisory Committee of Health Research, July, Pan American Health Organization, Division of Health and Human Development, Washington. Retrieved from: http://www.paho.org/English/HDP/HDR/ACHR-00-08.pdf.

Identifiers

ISSN

1644-9584